Bristol-Myers says cancer drug combo reduces death risk

April 16 (Reuters) - Bristol-Myers Squibb said on Monday its cancer drugs, Opdivo and Yervoy, reduced the risk of the disease spreading or death in previously untreated patients with a type of lung cancer.

Reuters

Bristol-Myers Squibb

Business and Financial News
Short URL

Latest News

Los Angeles Times: Monday’s TV highlights: 'The Big Bang Theory' on CBS

Daily Mail: London copper eases from 10-week top in holiday-thinned...

Daily Mail: Nadia Bartel and fellow NRL WAGs prepare for Brownlow Medal red carpet arrivals

CNBC: The US has an 'extremely strong economy' now: Strategist

CNBC: China is 'a little confused' on what the US wants on trade: Expert

CNBC: Asia markets to remain volatile in lead up to US midterms: Analyst

CNBC: CEO of Hong Kong's MTR hails new high speed line to Mainland China a success

Reuters: Singapore competition watchdog fines Grab, Uber $9.5 million

Reuters: Singapore competition watchdog fines Grab, Uber $9.5 mln

Reuters: Singapore competition watchdog fines Grab, Uber $9.5 million

FOX: Vietnam to hold state funeral for President Tran Dai Quang

Los Angeles Times: Rams starting corners Aqib Talib and Marcus Peters injure legs and probably will miss Thursday's game against Minnesota

USA Today: Red Wings use 2nd-period spree to beat Penguins 3-2

Daily Mail: Bachelor Nick Cummins encounters 'dad from hell' during hometown

Daily Mail: Support for Australian government edges higher but...

Daily Mail: Jordan Barrett puffs on a cigarette in New York

Daily Mail: The Bachelor Nick Cummins encounters 'dad from hell' during hometown visit

ABC: Justin Rose ties for fourth at finale, wins $10 million FedEx Cup

Daily Mail: Asian markets fall on new trade worries in thinned...

Daily Mail: Singapore competition watchdog fines Grab, Uber $9.5 mln

CTV News: Vintage Vancouver cafe named among top 50 in the world

FOX: Levin: Democrats and the judicial confirmation process

16 Related Articles, between 2018-03-22 and 2018-02-14

BRIEF-Bristol-Myers CEO's 2017 Total Compensation $18.7 Mln. * BRISTOL-MYERS SQUIBB CO - CEO GIOVANNI CAFORIO'S 2017 TOTAL COMPENSATION $18.7 MILLION VERSUS $16.9 MILLION IN 2016 - SEC FILING >>

BRIEF-Bristol-Myers Squibb And Illumina Announce Collaboration To Develop Companion Diagnostics For Bristol-Myers Squibb's Oncology Immunotherapies. * BRISTOL-MYERS SQUIBB AND ILLUMINA ANNOUNCE STRATEGIC COLLABORATION TO DEVELOP AND COMMERCIALIZE COMPANION DIAGNOSTICS FOR BRISTOL-MYERS SQUIBB’S ONCOLOGY IMMUNOTHERAPIES >>

BRIEF-Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Approval Of Opdivo Four-Week Dosing Schedule For Advanced Melanoma And Previously Treated Renal Cell Carcinoma. * BRISTOL-MYERS SQUIBB RECEIVES POSITIVE CHMP OPINION RECOMMENDING APPROVAL OF OPDIVO FOUR-WEEK DOSING SCHEDULE FOR ADVANCED MELANOMA AND PREVIOUSLY TREATED RENAL CELL CARCINOMA >>

BRIEF-Bristol-Myers Squibb Says Board Size Increased To 12. * BRISTOL-MYERS SQUIBB CO SAYS SIZE OF BOARD WAS INCREASED TO 12, EFFECTIVE MARCH 1, IN CONNECTION WITH JOSE BASELGA'S ELECTION - SEC FILING Source: (http://bit.ly/2CSll5M) Further company coverage: >>

BRIEF-Bristol-Myers Squibb Says Cancer Drug Combo Reduces Death Risk By 42 Pct. * OPDIVO PLUS LOW-DOSE YERVOY COMBINATION REDUCES THE RISK OF PROGRESSION OR DEATH BY 42% VERSUS CHEMOTHERAPY IN FIRST-LINE LUNG CANCER PATIENTS WITH HIGH TUMOR MUTATIONAL BURDEN (TMB) >>

BRIEF-Mercy Investment Services Says Urges Bristol Myers Shareholders To Vote For Proposal #4. * MERCY INVESTMENT SERVICES - AT BRISTOL-MYERS SHAREHOLDERS’ MEETING, SHAREHOLDERS WILL HAVE CHANCE TO VOTE ON PROPOSAL SPONSORED BY MULTIPLE SHAREHOLDERS >>

BRIEF-Sirenas Enters Into Multi-Target Collaboration With Bristol-Myers Squibb. * SIRENAS ENTERS INTO MULTI-TARGET COLLABORATION WITH BRISTOL-MYERS SQUIBB >>

Bristol-Myers and Merck meet cancer study goals. CNBC's Meg Tirrell reports the latest results on cancer studies from drug giants Merck and Bristol-Myers. >>

Bristol-Myers inks $1.85 billion cancer drug deal. CNBC's Meg Tirrell looks at Bristol-Myers buying the drug testing rights for a cancer drug from Nektar Therapeutics. >>

Bristol-Myers says cancer drug combo reduces death risk. April 16 (Reuters) - Bristol-Myers Squibb said on Monday its cancer drugs, Opdivo and Yervoy, reduced the risk of the disease spreading or death in... >>

Bristol-Myers to pay $1.85 billion in cancer deal with Nektar. (Reuters) - Bristol-Myers Squibb Co will pay Nektar Therapeutics $1.85 billion in cash and share purchase for a global development and commercialization deal on a promising Nektar cancer drug, the companies announced on Wednesday. >>

Bristol-Myers to pay $1.85 bln in cancer deal with Nektar. By Bill BerkrotFeb 14 (Reuters) - Bristol-Myers Squibb Co will pay Nektar Therapeutics $1.85 billion in cash and share purchase for a global development... >>

Merck, Bristol-Myers cancer drugs both beat expectations, but Merck beats them a little more. The medicines, which help unleash the immune system on cancer cells, were tested in patients with advanced lung cancer. >>

Merck, Bristol-Myers immunotherapies impress in key lung cancer trials. April 16 (Reuters) - Merck & Co's immunotherapy Keytruda plus chemotherapy significantly improved overall survival versus chemotherapy alone in newly-diagnosed patients with advanced non-small cell lung cancer in a highly-anticipated study that appears to cement the company's lead in the most lucrative oncology market. >>

Merck, Bristol-Myers immunotherapies impress in key.... By Bill BerkrotApril 16 (Reuters) - Merck & Co's immunotherapy Keytruda plus chemotherapy significantly improved overall survival versus chemotherapy... >>

UPDATE 1-Bristol-Myers to pay $1.85 bln in cancer deal with Nektar. Feb 14 (Reuters) - Bristol-Myers Squibb Co will pay Nektar Therapeutics $1.85 billion for a global development and profit-sharing deal on a promising Nektar cancer drug, the companies announced on Wednesday. >>

Reuters: Bristol-Myers says cancer drug combo reduces death risk

Latest News

16 Related Articles, between 2018-03-22 and 2018-02-14